These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 32441643)
1. Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice. Calderón-Goercke M; Castañeda S; Aldasoro V; Villa I; Prieto-Peña D; Atienza-Mateo B; Patiño E; Moriano C; Romero-Yuste S; Narváez J; Gómez-Arango C; Pérez-Pampín E; Melero R; Becerra-Fernández E; Revenga M; Álvarez-Rivas N; Galisteo C; Sivera F; Olivé-Marqués A; Álvarez Del Buergo M; Marena-Rojas L; Fernández-López C; Navarro F; Raya E; Galindez-Agirregoikoa E; Arca B; Solans-Laqué R; Conesa A; Hidalgo C; Vázquez C; Román-Ivorra JA; Loricera J; Lluch P; Manrique-Arija S; Vela P; De Miguel E; Torres-Martín C; Nieto JC; Ordas-Calvo C; Salgado-Pérez E; Luna-Gomez C; Toyos-Sáenz de Miera FJ; Fernández-Llanio N; García A; Larena C; González-Vela C; Corrales A; Varela-García M; Aurrecoechea E; Dos Santos R; García-Manzanares Á; Ortego N; Fernández S; Ortiz-Sanjuán F; Corteguera M; Hernández JL; González-Gay MÁ; Blanco R Clin Exp Rheumatol; 2020; 38 Suppl 124(2):112-119. PubMed ID: 32441643 [TBL] [Abstract][Full Text] [Related]
2. Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial. Spiera R; Unizony SH; Bao M; Luder Y; Han J; Pavlov A; Stone JH Semin Arthritis Rheum; 2021 Apr; 51(2):469-476. PubMed ID: 33784598 [TBL] [Abstract][Full Text] [Related]
3. Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice. Calderón-Goercke M; Loricera J; Aldasoro V; Castañeda S; Villa I; Humbría A; Moriano C; Romero-Yuste S; Narváez J; Gómez-Arango C; Pérez-Pampín E; Melero R; Becerra-Fernández E; Revenga M; Álvarez-Rivas N; Galisteo C; Sivera F; Olivé-Marqués A; Álvarez Del Buergo M; Marena-Rojas L; Fernández-López C; Navarro F; Raya E; Galindez-Agirregoikoa E; Arca B; Solans-Laqué R; Conesa A; Hidalgo C; Vázquez C; Román-Ivorra JA; Lluch P; Manrique-Arija S; Vela P; De Miguel E; Torres-Martín C; Nieto JC; Ordas-Calvo C; Salgado-Pérez E; Luna-Gomez C; Toyos-Sáenz de Miera FJ; Fernández-Llanio N; García A; Larena C; Palmou-Fontana N; Calvo-Río V; Prieto-Peña D; González-Vela C; Corrales A; Varela-García M; Aurrecoechea E; Dos Santos R; García-Manzanares Á; Ortego N; Fernández S; Ortiz-Sanjuán F; Corteguera M; Hernández JL; González-Gay MÁ; Blanco R Semin Arthritis Rheum; 2019 Aug; 49(1):126-135. PubMed ID: 30655091 [TBL] [Abstract][Full Text] [Related]
4. Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients. Calderón-Goercke M; Loricera J; Moriano C; Castañeda S; Narváez J; Aldasoro V; Maiz O; Melero R; Villa JI; Vela P; Romero-Yuste S; Callejas JL; de Miguel E; Galíndez-Agirregoikoa E; Sivera F; Fernández-López JC; Galisteo C; Ferraz-Amaro I; Sanchéz-Martín J; Sánchez-Bilbao L; González-Gay MA; Hernández JL; Blanco R; Clin Exp Rheumatol; 2023 Apr; 41(4):829-836. PubMed ID: 36377586 [TBL] [Abstract][Full Text] [Related]
5. The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis-study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study. Kreis L; Dejaco C; Schmidt WA; Németh R; Venhoff N; Schäfer VS Trials; 2024 Jan; 25(1):56. PubMed ID: 38225579 [TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations. Unizony S; McCulley TJ; Spiera R; Pei J; Sidiropoulos PN; Best JH; Birchwood C; Pavlov A; Stone JH Arthritis Res Ther; 2021 Jan; 23(1):8. PubMed ID: 33407817 [TBL] [Abstract][Full Text] [Related]
7. New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. Stone JH; Spotswood H; Unizony SH; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Spiera R; Bao M Rheumatology (Oxford); 2022 Jul; 61(7):2915-2922. PubMed ID: 34718434 [TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial. Strand V; Dimonaco S; Tuckwell K; Klearman M; Collinson N; Stone JH Arthritis Res Ther; 2019 Feb; 21(1):64. PubMed ID: 30786937 [TBL] [Abstract][Full Text] [Related]
9. Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study. Schmitt C; Brockwell L; Giraudon M; Zucchetto M; Christ L; Bannert B; Daikeler T; Villiger PM Arthritis Res Ther; 2022 Jun; 24(1):133. PubMed ID: 35659282 [TBL] [Abstract][Full Text] [Related]
10. Tocilizumab in giant cell arteritis: an update for the clinician. Ford JA; Gewurz D; Gewurz-Singer O Curr Opin Rheumatol; 2023 May; 35(3):135-140. PubMed ID: 36912060 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tocilizumab in giant cell arteritis: a single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool. Sebastian A; Kayani A; Prieto-Pena D; Tomelleri A; Whitlock M; Mo J; van der Geest N; Dasgupta B RMD Open; 2020 Nov; 6(3):. PubMed ID: 33161376 [TBL] [Abstract][Full Text] [Related]
12. Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data. Gale S; Trinh H; Tuckwell K; Collinson N; Stone JH; Sarsour K; Pei J; Best J; Birchwood C; Mohan SV Rheumatol Ther; 2019 Mar; 6(1):77-88. PubMed ID: 30707391 [TBL] [Abstract][Full Text] [Related]
13. A multicentre, large-scale, observational study of tocilizumab in patients with giant cell arteritis in Japan. Harigai M; Miyamae T; Hashimoto H; Umetsu K; Yamashita K; Nakaoka Y Mod Rheumatol; 2024 Jul; 34(4):775-783. PubMed ID: 37522620 [TBL] [Abstract][Full Text] [Related]